Longevity Biomarkers: Which Health Markers Are Worth Tracking Over Time?

Editorial draft for physician review. Not medically reviewed or approved for publication.

This educational article explains a common clinical question and does not replace individualized evaluation.

What makes a useful longevity marker?

The most useful marker is not necessarily the newest. It is a measurement that reliably changes a clinical decision, predicts a meaningful outcome, or helps monitor a proven intervention. A single laboratory result rarely captures overall healthspan. Age, symptoms, family history, medication use and trends over time all affect interpretation.

Cardiometabolic markers with established clinical value

Blood pressure, lipid measures, glucose or HbA1c when indicated, and smoking status have strong connections to cardiovascular and metabolic risk. ApoB can help quantify the number of atherogenic particles in selected patients, particularly when triglycerides are elevated or conventional cholesterol values are discordant. Lp(a) is largely genetically determined and is generally assessed at least once rather than repeatedly as a short-term lifestyle-response marker. Kidney function, including estimated GFR and urine albumin when appropriate, can add important risk information. Testing should be individualized rather than ordered as a universal large panel.

Functional markers: VO2 max and body composition

Cardiorespiratory fitness is strongly associated with long-term outcomes in observational research, but a VO2 max score alone is not a diagnosis or proof of longer life. Serial measurements are most meaningful with comparable protocols. DXA body composition can help contextualize lean mass and fat distribution, but hydration, instrument settings and other factors can affect comparisons. Neither test replaces clinical assessment.

Biological age, telomeres and epigenetic clocks

Commercial biological-age tests may measure interesting associations with age-related biology. Their reproducibility, clinical action thresholds and evidence that acting on the result improves hard outcomes are less established than for blood pressure or LDL-related risk. Telomere length varies across individuals and methods. These tests should not be presented as definitive measures of remaining lifespan or as validated proof that a treatment reversed aging.

A practical follow-up plan

Start with a defined question: prevention, treatment monitoring, fitness progress or evaluation of symptoms. Establish a baseline only where the result will guide care, use consistent measurement methods, and set reassessment intervals according to the marker and intervention. Avoid treating every small fluctuation as meaningful. A clinician should evaluate abnormal results in context and distinguish established preventive measures from experimental longevity approaches.

Clinical review requested

Physician input needed: Which markers are routinely offered in the practice’s $2,500 and $5,000 longevity programs? Which are optional, and which testing intervals are actually used? Add a first-person clinical example only after Dr. Nazarian provides and approves it.

References and further reading

• American Heart Association — Life’s Essential 8
• 2024 National Lipid Association focused update on Lp(a)
• National Institute on Aging — Biomarkers of Aging

Related clinical service: https://www.myconciergemd.com/services/longevity-anti-aging-medicine/biological-age-testing-los-angeles/.

Medically reviewed by David Nazarian, MD on November 11, 2026